Table 2.

Response rate and clinical benefit by NRAS status

NRAS-mutantBRAF-mutantWTP valuea
Best response to any line of immune therapyn = 60n = 53n = 116
 CR/PR19 (32%)12 (23%)22 (19%)0.068
 SD/PD41 (68%)41 (77%)94 (81%)
 CR/PR/SD30 (50%)16 (30%)34 (29%)0.004
 PD30 (50%)37 (70%)82 (71%)
Response to first-line immune therapyn = 60n = 53n = 116
 CR/PR17 (28%)8 (15%)19 (16%)0.037
 SD/PD43 (72%)45 (85%)97 (84%)
 CR/PR/SD27 (45%)13 (25%)31 (27%)0.006
 PD33 (55%)40 (75%)85 (73%)

Abbreviations: PD, progressive disease; SD, stable disease.

  • aPearson χ2 test P value for NRAS-mutant versus non–NRAS-mutant patients.